Loading
Every dose of doxorubicin adds to a lifetime total; above roughly 450 mg/m2 heart failure risk rises steeply, so sarcoma and lymphoma regimens are capped and hearts are monitored.
Every dose of doxorubicin adds to a lifetime cumulative total, and this caution pairing links the anthracycline with cardio-oncology because the risk of heart failure rises steeply above roughly 450 mg/m2. The mechanism is topoisomerase II beta-mediated damage to cardiomyocytes that is dose-dependent and irreversible, and the risk is higher with chest radiotherapy, trastuzumab and at the extremes of age. Decades of cohort data and randomised trials of dexrazoxane support the warning, and mitigation includes dexrazoxane, liposomal doxorubicin, continuous infusion and echocardiographic surveillance. The caution applies in sarcoma, Hodgkin lymphoma, diffuse large B-cell lymphoma and triple-negative breast cancer, where regimens are capped and hearts are monitored.
Shares Cardio-oncology, Doxorubicin, Sarcomas (soft tissue, bone, GIST), Diffuse large B-cell lymphoma.
Shares Cardio-oncology, Doxorubicin, Hodgkin lymphoma, Diffuse large B-cell lymphoma.
Shares Cardio-oncology, Doxorubicin, Hodgkin lymphoma, Sarcomas (soft tissue, bone, GIST).
Shares Cardio-oncology, Doxorubicin, Sarcomas (soft tissue, bone, GIST), Diffuse large B-cell lymphoma.
Shares Cardio-oncology, Doxorubicin, Hodgkin lymphoma, Sarcomas (soft tissue, bone, GIST).
Shares Cardio-oncology, Doxorubicin, Hodgkin lymphoma, Sarcomas (soft tissue, bone, GIST).
Shares Cardio-oncology, Hodgkin lymphoma.